
Trusted and proven counsel for your complex deal and disclosure issues
Our integrated Capital Markets and Public Company Advisory platform advises issuers and underwriters of securities, boards of directors and management teams of public companies, helping navigate complex regulatory landscapes and evolving market conditions to achieve financing objectives and satisfy compliance obligations.

Market Edge
Our blog provides timely insights and market trends for issuers and underwriters, public company boards and management teams, enabling you to stay apprised of current developments and best practices in the capital markets and corporate governance.
DLA Piper’s Capital Markets and Public Company Advisory group supports issuers and underwriters of equity and debt securities in achieving their strategic priorities. We combine practical advice with up-to-date insights to help execute capital-raising deals on optimal terms.
We serve as trusted advisors to management teams, boards of directors, and special committees of more than 100 public companies, helping them navigate a complex regulatory and governance environment. We help issuers prepare for and comply with emerging Securities and Exchange Commission (SEC), Nasdaq, and New York Stock Exchange (NYSE) requirements and pursue expansion, financing, M&A, and other business strategies in creative ways.
“The DLA Piper team instills confidence in us, provides outstanding legal services and consistently delivers positive results.”
Resources
Events
Biotech & Medtech Bootcamp: Exclusive event for pre-IPO and growth-stage companies. Gain insights on regulatory, compliance, IP, and capital markets strategies from investors, investment bankers, attorneys and industry experts.
Deals
Rare Earths Americas
Initial Public Offering
US$69 million
May 2026
Einride
de-SPAC
US$1.8 billion
November 2025
Intuitive machines
PIPE*
US$175 million
February 2026
Titan
At-the market Offering**
US$50 million
January 2026
Strive
Follow-on Offering and Note Exchange Offer*
US$208.8 million
January 2026
Rezolve.Ai
Direct Offering
US$250 million
January 2026
Elicio Therapeutics
At-the-market Offering*
US$100 million
January 2026
CleanSpark
Convertible Senior Notes*
US$1.15 billion
November 2025
* Underwriter / Placement Agent Representation
** Sales Agent Representation









